GOVX

GeoVax Labs, Inc.
CAPPED RATING

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

GeoVax Labs, Inc. (GOVX) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.5 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
F
Factor Score 0.3 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.5
EV / EBITDA -0.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -87.5%
Price Return 12M -99.3%
Catalyst Signal 0.00
Market Cap $21.8M
TTM Revenue $0.0
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D+ (1.8) F (0.3) F (0.3) C+ (2.6) D+ (1.5)
2026-11-05 A- (3.9) D+ (1.8) F (0.3) F (0.4) C+ (2.7) D+ (1.8)
2026-10-29 B+ (3.7) D+ (1.8) F (0.3) F (0.5) C+ (2.7) D+ (1.8)
2026-10-22 B+ (3.7) C- (1.9) F (0.3) F (0.4) C+ (2.6) D+ (1.8)
2026-10-15 B+ (3.7) D+ (1.8) F (0.3) F (0.5) C+ (2.6) D+ (1.8)
Page 1 of 5